Vaxcyte, Inc.
MUN:5VA 株式レポート
Vaxcyte マネジメント 主要情報 CEO給与比率 5.3% CEO在任期間 11yrs CEOの所有権 0.5% 経営陣の平均在職期間 4.5yrs 取締役会の平均在任期間 5.5yrs
経営陣の近況
Vaxcyte Appoints John Furey to Board of Directors Jul 02 Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024 Apr 16
Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer Jan 17
Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors Nov 29
Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023 Dec 13
High number of new directors Nov 28
すべての更新を表示 Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion. Sep 06
New major risk - Revenue and earnings growth Sep 04 Vaxcyte, Inc. has filed a Follow-on Equity Offering. Sep 04
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older Sep 03
Vaxcyte Appoints John Furey to Board of Directors Jul 02 Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024 Apr 16
New major risk - Revenue and earnings growth Mar 12
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants Mar 05
Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 16 Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million. Feb 01
Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.
Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer Jan 17
Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise Jan 05
Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases Dec 05
Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors Nov 29
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Nov 10
Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Oct 20
New major risk - Shareholder dilution Aug 29
Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 17
Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults Jan 06
Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023 Dec 13
High number of new directors Nov 28
High number of new directors Oct 28
Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64 Oct 25
Vaxcyte, Inc. Announces Executive Appointments Oct 12
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older Sep 07
Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs Aug 06
Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs Aug 05
Vaxcyte, Inc. Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of Vax-24 in Adults Jul 13
High number of new directors Jun 07
CEO報酬分析 Vaxcyte の収益と比較して、Grant Pickering の報酬はどのように変化したか？ 日付 総報酬 給与 会社業績 Sep 30 2024 n/a n/a -US$508m
Jun 30 2024 n/a n/a -US$497m
Mar 31 2024 n/a n/a -US$437m
Dec 31 2023 US$12m US$640k -US$402m
Sep 30 2023 n/a n/a -US$300m
Jun 30 2023 n/a n/a -US$265m
Mar 31 2023 n/a n/a -US$245m
Dec 31 2022 US$14m US$601k -US$223m
Sep 30 2022 n/a n/a -US$174m
Jun 30 2022 n/a n/a -US$143m
Mar 31 2022 n/a n/a -US$118m
Dec 31 2021 US$5m US$575k -US$100m
Sep 30 2021 n/a n/a -US$92m
Jun 30 2021 n/a n/a -US$87m
Mar 31 2021 n/a n/a -US$83m
Dec 31 2020 US$3m US$481k -US$89m
Sep 30 2020 n/a n/a -US$83m
Jun 30 2020 n/a n/a -US$73m
Mar 31 2020 n/a n/a -US$64m
Dec 31 2019 US$596k US$426k -US$50m
報酬と市場: Grantの 総報酬 ($USD 12.14M ) は、 German市場 ($USD 5.11M ) の同規模の企業の平均を上回っています。
報酬と収益: Grantの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者 Mr. Grant E. Pickering, M.B.A., is Co-Founder of Vaxcyte, Inc. since 2013 and has been its Chief Executive Officer and Director since November 2013 and served as its President since November 2013 until Dec ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 Co-Founder 11yrs US$12.14m 0.53% € 64.5m President & CFO 4.5yrs US$5.42m 0.059% € 7.2m Executive VP & COO 4.9yrs US$5.40m 0.14% € 16.9m Senior VP 2.6yrs US$3.49m 0.0081% € 985.6k Co-Founder 11.8yrs データなし データなし Co-Founder & VP of Research no data データなし データなし Senior VP of Finance & Principal Accounting Officer 1.8yrs データなし 0.0031% € 379.9k Senior Vice President of Corporate Communications & Investor Relations no data データなし データなし Chief People Officer less than a year データなし データなし Senior Vice President of Process Development & Manufacturing 8.6yrs US$2.35m データなし Senior Vice President of Commercial Manufacturing & Supply Chain 3yrs US$1.84m データなし Senior Vice President of Project Management no data データなし データなし
もっと見る
経験豊富な経営陣: 5VAの経営陣は 経験豊富 であると考えられます ( 4.5年の平均在職年数)。
取締役 名称 ポジション 在職期間 報酬 所有権 Co-Founder 11yrs US$12.14m 0.53% € 64.5m Independent Director 3.2yrs US$704.22k 0.0045% € 547.4k Independent Director 8.2yrs US$696.72k 0.010% € 1.2m Independent Director 6.5yrs US$691.72k 0.0045% € 547.4k Independent Director 4.6yrs US$704.22k 0.0045% € 547.4k Member of Scientific Advisory Board no data データなし データなし Independent Chairman of the Board 3.1yrs US$724.22k 0.0045% € 547.4k Member of Scientific Advisory Board no data データなし データなし Member of Scientific Advisory Board 7.8yrs データなし データなし Independent Director 3.2yrs US$704.22k 0.0045% € 547.4k Member of Scientific Advisory Board no data データなし データなし Member of Scientific Advisory Board no data データなし データなし
もっと見る
経験豊富なボード: 5VAの 取締役会 は 経験豊富 であると考えられます ( 5.5年の平均在任期間)。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}